

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **FRONTAGE HOLDINGS CORPORATION**

**方達控股公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1521)**

### **(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 28, 2025 AND (2) CHANGE OF DIRECTORS**

#### **POLL RESULTS OF THE AGM**

The Board is pleased to announce that all the resolutions proposed at the AGM held on May 28, 2025 were duly passed by way of poll.

#### **CHANGE OF DIRECTORS**

The Board is pleased to further announce that with effect from the conclusion of the AGM on May 28, 2025, Dr. Zhihe Li ceased to be a Non-executive Director of the Company, while Dr. Wentao Zhang and Dr. Zhongping Lin were appointed as Executive Directors of the Company.

#### **POLL RESULTS OF THE AGM**

The board (the “**Board**”) of directors (the “**Directors**”) of Frontage Holdings Corporation (the “**Company**”) is pleased to announce the voting results of the annual general meeting of the Company (the “**AGM**”) held on Wednesday, May 28, 2025. Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the circular of the Company dated April 24, 2025 (the “**Circular**”).

All the resolutions proposed at the AGM were taken by poll. The Company’s branch share registrar in Hong Kong, Tricor Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

As at the date of the AGM, the total number of issued Shares was 2,035,724,910 Shares (including 3,536,000 Shares which have been repurchased and were yet to be cancelled), and holders of 2,032,188,910 Shares were entitled to attend and vote for or against all the resolutions proposed at the AGM. The Company does not have any treasury shares (as defined under the Listing Rules).

There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Listing Rules and no Shareholders were required to abstain from voting at the AGM under the Listing Rules. No Shareholders had indicated in the Circular that they intended to vote against or to abstain from voting on any resolutions at the AGM.

The poll results in respect of the respective resolutions proposed at the AGM are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company and the reports of the Directors and auditor of the Company for the year ended December 31, 2024.	511,207,996 (100.000%)	0 (0.000%)
2(a).	To appoint Dr. Wentao Zhang as an Executive Director.	511,207,996 (100.000%)	0 (0.000%)
2(b).	To appoint Dr. Zhongping Lin as an Executive Director.	511,207,996 (100.000%)	0 (0.000%)
2(c).	To re-elect Ms. Zhuan Yin as a Non-executive Director.	511,207,996 (100.000%)	0 (0.000%)
2(d).	To re-elect Mr. Hao Wu as a Non-executive Director.	509,063,038 (99.580%)	2,144,958 (0.420%)
2(e).	To authorize the Board to fix the respective Directors' remuneration.	511,207,996 (100.000%)	0 (0.000%)
3.	To re-appoint BDO Limited as the Company's auditor and to authorize the Board to fix their remuneration.	509,047,038 (99.577%)	2,160,958 (0.423%)
4.	To grant a general and unconditional mandate to the Directors to repurchase Shares not exceeding 10% of the total number of Shares (excluding any treasury shares) as at the date of passing of this resolution.	511,207,996 (100.000%)	0 (0.000%)
5.	To grant a general and unconditional mandate to the Directors to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of Shares (excluding any treasury shares) as at the date of passing of this resolution.	509,063,038 (99.580%)	2,144,958 (0.420%)
6.	Conditional upon resolutions 4 and 5 being passed, to extend the general mandate granted to the Directors to issue, allot and deal with additional Shares by the aggregate number of Shares repurchased by the Company.	509,063,038 (99.580%)	2,144,958 (0.420%)
7.	To grant the Board an authorization to grant awards pursuant to the post-IPO share incentive plan adopted by the Company on May 11, 2019 in respect of a maximum number of 85,823,591 Shares and to authorize the Board to allot, issue and deal with Shares in respect of which awards are granted.	509,047,038 (99.577%)	2,160,958 (0.423%)

# The full text of the resolutions numbered 4 to 7 above are set out in the notice of the AGM dated April 24, 2025.

As more than 50% of the votes were cast in favour of each of the resolutions above, the resolutions numbered 1 to 7 were duly passed as ordinary resolutions of the Company by way of poll at the AGM.

Dr. Song Li, Mr. Hao Wu, Ms. Zhuan Yin, Mr. Yifan Li, and Mr. Erh Fei Liu attended the AGM in person or by electronic means while Dr. Zhihe Li and Dr. Jingsong Wang were unable to attend the AGM due to other business commitments.

## CHANGE OF DIRECTORS

With effect from the conclusion of the AGM on May 28, 2025, Dr. Zhihe Li ceased to be a Non-executive Director of the Company.

As set out in the Circular, Dr. Zhihe Li did not offer himself for re-election as he would retire as the Non-executive Director at the conclusion of the AGM. Dr. Zhihe Li has confirmed that he has no disagreement with the Board and there is nothing to be brought to the attention of the Shareholders or the Stock Exchange in relation to his retirement.

With effect from the conclusion of the AGM on May 28, 2025, Dr. Wentao Zhang and Dr. Zhongping Lin were appointed as Executive Directors of the Company. The biographical details of Dr. Wentao Zhang and Dr. Zhongping Lin are as follows:

**Dr. Wentao Zhang**, aged 56, was appointed as a Co-Chief Executive Officer on January 6, 2025. Dr. Zhang has been serving as the chief strategy officer of Frontage Labs since August 2024. He was an executive vice president of Frontage Labs between July 2021 and August 2024, responsible for global drug discovery services.

Prior to joining Frontage Labs, Dr. Zhang was the founder and chief executive officer of Quintara Discovery, Inc. (“**Quintara Discovery**”), a discovery & development specialist based in the San Francisco Bay Area providing high-quality in vitro absorption, distribution, metabolism, and excretion (ADME) profiling, Good Laboratory Practice (“**GLP**”) and non-GLP bioanalysis services. In July 2021, Quintara Discovery was acquired by Frontage Labs and became a wholly-owned subsidiary of Frontage Labs.

Before founding Quintara Discovery, Dr. Zhang served as the senior director at Exelixis, Inc., a biotechnology company focused on small molecule therapies for cancer and other serious diseases. Earlier in his career, Dr. Zhang worked at Genelabs Technologies, Inc. as a staff scientist from 1999 to 2001. Between 1997 and 1999, Dr. Zhang completed a postdoctoral fellowship at the University of California, Berkeley, United States.

Dr. Zhang received his bachelor’s degree majoring in chemistry from Peking University, in July 1991, his master’s degree majoring in bioanalytical chemistry from Emory University, United States in May 1993, and his PhD degree majoring in biophysical chemistry from University of Wisconsin-Madison, United States in December 1996.

As at the date of this announcement, Dr. Zhang has been granted options to purchase 5,200,000 Shares pursuant to the Company’s 2018 Share Incentive Scheme. Accordingly, Dr. Zhang is interested in a total of 5,200,000 Shares within the meaning of Part XV of the SFO.

Save as disclosed above, as at the date of this announcement, Dr. Zhang (i) does not hold any other directorships in any other public companies the securities of which are listed in Hong Kong or overseas in the last three years; (ii) does not hold any other position with the Company and other members of the Group; (iii) does not have other major appointments and professional qualifications; and (iv) does not have any relationships with any Directors, senior management, substantial or controlling shareholders of the Company (each as defined in the Listing Rules).

**Dr. Zhongping Lin**, aged 61, was appointed as a Co-Chief Executive Officer on January 6, 2025. Dr. Lin has been serving as the president of Frontage Labs since January 2023. He was an executive vice president of the Company and Frontage Labs between 2017 and 2023, responsible for bioanalytical and biologics services. From 2007 to 2017, he was a senior vice president of Frontage Labs, responsible for bioanalytical and biologics services. Before joining Frontage Labs, he worked at AstraZeneca Pharmaceuticals LP as a scientist and later on was the business lead of the global drug metabolism and pharmacokinetics (DMPK) department. Prior to this, he worked at Avantix Laboratories, Inc. as a senior research scientist and a lab manager and director of bioanalytical chemistry from 2000 to 2005.

Dr. Lin also has extensive research and academic experience. He was a research associate at the College of Pharmacy, Comprehensive Cancer Center (CCC), James Cancer Hospital, Ohio State University, United States. From 1998 to 1999, he was a postdoctoral fellow at the Institute of Ocean Sciences, the Department of Fisheries and Oceans, Canada. Previously, he was a research and teaching assistant at Dalhousie University, United States. From 1987 to 1993, he was an analytical chemist and director at the Modern Instrumental Analysis Laboratory, Yunnan University.

Dr. Lin received his bachelor's degree majoring in chemistry from Fuzhou Normal College of East China University of Technology (formerly known as, Fuzhou Teacher's College), China in August 1982, his master's degree majoring in analytical chemistry from Yunnan University, China, in October 1987, and his PhD degree majoring in chemistry from Dalhousie University, Canada, in May 1998. He has also completed post-doctoral research in pharmacokinetics and metabolism at the College of Pharmacy and the Comprehensive Cancer Center (CCC) of Ohio State University. He is a member of the American Chemical Society in 2005 and a member of the American Association of Pharmaceutical Scientists. In addition, he is an author of numerous scientific publications.

As at the date of this announcement, Dr. Lin (i) is beneficial owner of 1,085,026 Shares; (ii) has been granted options to purchase 2,000,000 Shares pursuant to the Company's pre-IPO 2015 Share Incentive Plan, which have been fully vested; (iii) has been granted options to purchase 6,700,000 Shares pursuant to the Company's 2018 Share Incentive Scheme. Accordingly, as at the date of this announcement, Dr. Lin is interested in a total of 9,785,026 Shares within the meaning of Part XV of the SFO.

Save as disclosed above, as at the date of this announcement, Dr. Lin (i) does not hold any other directorships in any other public companies the securities of which are listed in Hong Kong or overseas in the last three years; (ii) does not hold any other position with the Company and other members of the Group; (iii) does not have other major appointments and professional qualifications; and (iv) does not have any relationships with any Directors, senior management, substantial or controlling shareholders of the Company (each as defined in the Listing Rules).

The Company has entered into a director appointment letter with each of Dr. Wentao Zhang and Dr. Zhongping Lin relating to their services as Executive Directors for a term of 3 years commencing from May 28, 2025, pursuant to which neither Dr. Zhang nor Dr. Lin will be entitled to any additional remuneration as Executive Directors. Save as disclosed in the Circular and above, as at the date of this announcement, there is no other information which is required to be disclosed under Rule 13.51(2) of the Listing Rules and there is no other matter relating to appointment of each of Dr. Wentao Zhang and Dr. Zhongping Lin that needs to be brought to attention of the Shareholders or the Stock Exchange.

The Board would also like to take this opportunity to express its sincere gratitude to Dr. Zhihe Li for his valuable efforts and contributions to the Company during his tenure of service, and to welcome Dr. Wentao Zhang and Dr. Zhongping Lin as members of the Board.

By Order of the Board  
**Frontage Holdings Corporation**  
**Dr. Song Li**  
*Chairman*

Hong Kong, May 28, 2025

*As at the date of this announcement, the Board comprises Dr. Song Li, Dr. Wentao Zhang and Dr. Zhongping Lin as executive directors; Ms. Zhuan Yin and Mr. Hao Wu as non-executive directors; and Mr. Yifan Li, Mr. Erh Fei Liu and Dr. Jingsong Wang as independent non-executive directors.*

*\* For identification purpose only*